BIO-TECHNE Corp Restructuring Charges
BIO-TECHNE Corp (TECH) reported Restructuring Charges of $21.07 million for the 3-month period ending 2024-06-30, per its 10-K filed 2024-08-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-08-22
- BIO-TECHNE Corp restructuring charges for the quarter ending 2024-06-30 was $21.07M.
- BIO-TECHNE Corp restructuring charges for the quarter ending 2024-03-31 was $1.27M.
- BIO-TECHNE Corp restructuring charges for the quarter ending 2023-12-31 was $11.42M.
- BIO-TECHNE Corp restructuring charges for the quarter ending 2023-09-30 was -$21.52M.
- BIO-TECHNE Corp restructuring charges for fiscal 2024 was $12.24M, a 219.80% increase from fiscal 2023.
- BIO-TECHNE Corp restructuring charges for fiscal 2023 was $3.83M, a 133.48% increase from fiscal 2022.
- BIO-TECHNE Corp restructuring charges for fiscal 2022 was $1.64M, a 1054.93% increase from fiscal 2021.
- BIO-TECHNE Corp restructuring charges for fiscal 2021 was $142.00K, a 63.22% increase from fiscal 2020.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2024-06-30 | $21.07M 10-K · filed 2024-08-22 | $22.34M derived: sum of 2 quarters · filed 2024-08-22 | $33.77M derived: sum of 3 quarters · filed 2024-08-22 | $12.24M 10-K · filed 2024-08-22 |
| 2024-03-31 | $1.27M 10-K · filed 2024-08-22 | $12.70M derived: sum of 2 quarters · filed 2024-08-22 | -$8.83M derived: sum of 3 quarters · filed 2024-08-22 | |
| 2023-12-31 | $11.42M 10-K · filed 2024-08-22 | $11.42M 10-Q · filed 2024-02-07 | ||
| 2023-09-30 | -$21.52M derived: 10-K 12 month − 3 quarters · filed 2024-08-22 | |||
| 2023-06-30 | $3.83M 10-K · filed 2024-08-22 | |||
| 2022-06-30 | $242.00K 10-K · filed 2022-08-24 | $1.64M 10-K · filed 2024-08-22 | ||
| 2021-12-31 | $242.00K 10-Q · filed 2022-05-09 | $1.43M derived: sum of 2 quarters · filed 2022-05-09 | ||
| 2021-09-30 | $1.19M 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $142.00K 10-K · filed 2023-08-23 | |||
| 2020-06-30 | $87.00K 10-K · filed 2022-08-24 | |||
| 2018-06-30 | $376.00K 10-K/A · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |